Skip to main content

Research Repository

Advanced Search

Impact of Tumour Epstein–Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL

Nohtani, Mahdi; Vrzalikova, Katerina; Ibrahim, Maha; Powell, Judith E.; Fennell, Éanna; Morgan, Susan; Grundy, Richard; McCarthy, Keith; Dewberry, Sarah; Bouchal, Jan; Bouchalova, Katerina; Kearns, Pamela; Murray, Paul G.

Impact of Tumour Epstein–Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL Thumbnail


Authors

Mahdi Nohtani

Katerina Vrzalikova

Maha Ibrahim

Judith E. Powell

Éanna Fennell

Susan Morgan

RICHARD GRUNDY richard.grundy@nottingham.ac.uk
Professor of Paediatric Neuro-Oncology

Keith McCarthy

Sarah Dewberry

Jan Bouchal

Katerina Bouchalova

Pamela Kearns

Paul G. Murray



Abstract

In this study, we have re-evaluated how EBV status influences clinical outcome. To accomplish this, we performed a literature review of all studies that have reported the effect of EBV status on patient outcome and also explored the effect of EBV positivity on outcome in a clinical trial of children with cHL from the UK. Our literature review revealed that almost all studies of older adults/elderly patients have reported an adverse effect of an EBV-positive status on outcome. In younger adults with cHL, EBV-positive status was either associated with a moderate beneficial effect or no effect, and the results in children and adolescents were conflicting. Our own analysis of a series of 166 children with cHL revealed no difference in overall survival between EBV-positive and EBV-negative groups (p = 0.942, log rank test). However, EBV-positive subjects had significantly longer event-free survival (p = 0.0026). Positive latent membrane protein 1 (LMP1) status was associated with a significantly lower risk of treatment failure in a Cox regression model (HR = 0.21, p = 0.005). In models that controlled for age, gender, and stage, EBV status had a similar effect size and statistical significance. This study highlights the age-related impact of EBV status on outcome in cHL patients and suggests different pathogenic effects of EBV at different stages of life.

Citation

Nohtani, M., Vrzalikova, K., Ibrahim, M., Powell, J. E., Fennell, É., Morgan, S., …Murray, P. G. (2022). Impact of Tumour Epstein–Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL. Cancers, 14(17), Article 4297. https://doi.org/10.3390/cancers14174297

Journal Article Type Article
Acceptance Date Aug 16, 2022
Online Publication Date Sep 1, 2022
Publication Date Sep 1, 2022
Deposit Date Nov 9, 2022
Publicly Available Date Mar 28, 2024
Journal Cancers
Electronic ISSN 2072-6694
Publisher MDPI AG
Peer Reviewed Peer Reviewed
Volume 14
Issue 17
Article Number 4297
DOI https://doi.org/10.3390/cancers14174297
Keywords Epstein–Barr virus (EBV), classic Hodgkin lymphoma (cHL), clinical trial
Public URL https://nottingham-repository.worktribe.com/output/11742982
Publisher URL https://www.mdpi.com/2072-6694/14/17/4297

Files




You might also like



Downloadable Citations